Glover v. Cohen

CourtCourt of Appeals for the Federal Circuit
DecidedOctober 5, 2022
Docket21-2126
StatusUnpublished

This text of Glover v. Cohen (Glover v. Cohen) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Glover v. Cohen, (Fed. Cir. 2022).

Opinion

Case: 21-2126 Document: 26 Page: 1 Filed: 10/05/2022

NOTE: This disposition is nonprecedential.

United States Court of Appeals for the Federal Circuit ______________________

MORRIS S. GLOVER, Plaintiff-Appellant

v.

DANIEL E. COHEN, BRUCE C. JOHNSON, CREATIVE INTEGRATION & DESIGN, INC., Defendants-Appellees

SUZANNE KAMEESE, LOWELL FRENCH, Defendants ______________________

2021-2126 ______________________

Appeal from the United States District Court for the Western District of Pennsylvania in No. 2:19-cv-00734- WSH, Judge W. Scott Hardy. ______________________

Decided: October 5, 2022 ______________________

MORRIS S. GLOVER, Bedford Heights, OH, pro se.

KURT JOHN NIEDERLUECKE, Fredrikson & Byron, PA, Minneapolis, MN, for defendants-appellees. Also repre- sented by CARA S. DONELS, Des Moines, IA. ______________________ Case: 21-2126 Document: 26 Page: 2 Filed: 10/05/2022

Before DYK, TARANTO, and STARK, Circuit Judges. PER CURIAM. Morris S. Glover (“Glover”) appeals the final judgment of the United States District Court for the Western District of Pennsylvania following dismissal with prejudice of his complaint, which largely concerns the prior litigation Glover v. CNS, Inc., No. 95-02227 (N.D. Ohio). For the rea- sons below, we affirm. I Glover owns expired utility and design patents, U.S. Patent Nos. 5,466,456 (issued November 14, 1995) and D351,924 (issued October 25, 1994), which concern a facial cleanser and an ornamental design for a facial cleanser, re- spectively. In the current litigation, Glover appears to maintain his assertion, first made over twenty-five years ago, that his patents were infringed by a product called the Breathe Right® dilator, manufactured and sold by CNS, Inc. (“CNS”). In 1995, Glover sued CNS in the United States District Court for the Northern District of Ohio for infringing his patents. During that litigation, one of the Defendants in the current case, Bruce C. Johnson (“Johnson”), submitted a declaration asserting that he was the primary inventor of the Breathe Right® dilator and that he had transferred his rights in the device to Creative Integration & Design, Inc. (“CID”), which in turn granted CNS an exclusive license concerning the device. Johnson maintained that Glover had nothing to do with the invention of the Breathe Right® device. Similarly, current-Defendant Daniel E. Cohen (“Cohen”), then associated with CNS, submitted a declara- tion that Glover had nothing to do with the Breathe Right® device. The District Court eventually granted CNS’s mo- tion for summary judgment, finding no infringement. Case: 21-2126 Document: 26 Page: 3 Filed: 10/05/2022

GLOVER v. COHEN 3

Glover appealed, and we affirmed. See Glover v. CNS, Inc., 111 F.3d 144 (1997) (per curiam). In the instant case, brought in 2019, Glover appears to again assert that the Breathe Right® dilator infringes his patents. He alleges that in 1987 he submitted the idea for his invention to American Idea Management Corporation (“AIM”), an entity associated with Defendants Suzanne Kameese and Lowell French. Glover contends that AIM improperly conveyed his idea to Defendant CID, which in turn improperly conveyed his idea to Defendant Johnson. He also attacks various aspects of the evidence in the prior litigation. The caption of Glover’s Complaint indicates his claims are for “[p]atent infringement, conspiracy for a summary judgment making Plaintiff’s patents invalid,” “[d]enial of due process of law, VII Amendment to the Constitution which renders a void judgment,” and “42 U.S.C. §§ 1983, 1985, 1986.” Complaint at 1, Glover v. Cohen, No. 19-00734 (W.D. Pa. June 26, 2019). In his prayer for relief, Glover sought to void the summary judgment ruling from the prior litigation, reinstate his patents, and be provided an oppor- tunity to demonstrate infringement in a jury trial. Kameese, CID and Johnson, and Cohen filed three sep- arate motions to dismiss, each of which the District Court granted. 1 Glover timely appealed. We have jurisdiction pursuant to 28 U.S.C. § 1295(a)(1).

1 Glover thereafter filed a “Motion: Objection to the Court’s ‘Memorandum Opinion,’” which the District Court construed as an untimely motion for reconsideration, but nonetheless considered and denied. See Memorandum Or- der denying Plaintiff’s “Motion: Objection to the Court’s Memorandum Opinion,” Glover v. Cohen, No. 19-00734 (W.D. Pa. Mar. 25, 2021). Case: 21-2126 Document: 26 Page: 4 Filed: 10/05/2022

II We apply the law of the applicable regional circuit, here the Third Circuit, on issues of procedural law that do not implicate patent law, while we apply the law of our own circuit to issues of patent law. See Landmark Screens, LLC v. Morgan, Lewis, & Bockius, LLP, 676 F.3d 1354, 1361 (Fed. Cir. 2012). Thus, we apply regional circuit law to dis- missals under Fed. R. Civ. P. 12(b)(6), see Endo Pharms. Inc. v. Teva Pharms. USA, Inc., 919 F.3d 1347, 1352 (Fed. Cir. 2019); applications of issue preclusion, see Voter Veri- fied, Inc. v. Election Sys. & Software LLC, 887 F.3d 1376, 1382 (Fed. Cir. 2018); 2 and statute of limitations rulings, see id. Like the Third Circuit, we review a pro se litigant’s sub- missions liberally. See Higgs v. Atty. Gen. of the U.S., 655 F.3d 333, 339 (3d Cir. 2011); In re Steed, 802 F.3d 1311, 1317 (Fed. Cir. 2015). We apply de novo review to a Rule 12(b)(6) dismissal. See Endo Pharms., 919 F.3d at 1352 (applying Third Cir- cuit law). “To survive a motion to dismiss for failure to state a claim, a complaint must allege enough facts to state a claim to relief that is plausible on its face.” Id. (internal quotation marks omitted). Here, Glover failed to state any claim upon which relief could be granted. A Concerning patent infringement, Glover failed to state a claim upon which relief can be granted because his suit is barred by issue preclusion. Issue preclusion can be a proper basis for a Rule 12(b)(6) dismissal. See Leyse v. Bank of Am. Nat’l Ass’n, 804 F.3d 316, 320 (3d Cir. 2015).

2 Even if we were to conclude that Federal Circuit law applies to issue preclusion, the result would be the same. Case: 21-2126 Document: 26 Page: 5 Filed: 10/05/2022

GLOVER v. COHEN 5

Under this doctrine, a party cannot relitigate an issue that has already been litigated. See Peloro v. United States, 488 F.3d 163, 175 (3d Cir. 2007). That is the situation here. Glover litigated the same issue – patent infringement by the Breathe Right® dilator – in the Northern District of Ohio action and cannot relitigate that issue now. The Third Circuit generally applies plenary review to determinations of issue preclusion. See Jean Alexander Cosmetics, Inc. v. L’Oreal USA, Inc., 458 F.3d 244, 247-49 (3d Cir.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Jones v. R. R. Donnelley & Sons Co.
541 U.S. 369 (Supreme Court, 2004)
Wallace v. Kato
127 S. Ct. 1091 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Dique v. New Jersey State Police
603 F.3d 181 (Third Circuit, 2010)
Higgs v. ATTY. GEN. OF THE US
655 F.3d 333 (Third Circuit, 2011)
Landmark Screens, LLC v. Morgan, Lewis, & Bockius, LLP
676 F.3d 1354 (Federal Circuit, 2012)
Timothy Dotson v. N. Lane, Jr.
360 F. App'x 617 (Sixth Circuit, 2010)
In Re: Steed
802 F.3d 1311 (Federal Circuit, 2015)
Alston v. Parker
363 F.3d 229 (Third Circuit, 2004)
Leyse v. Bank of America National Ass'n
804 F.3d 316 (Third Circuit, 2015)
Voter Verified, Inc. v. Election Sys. & Software LLC
887 F.3d 1376 (Federal Circuit, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
Glover v. Cohen, Counsel Stack Legal Research, https://law.counselstack.com/opinion/glover-v-cohen-cafc-2022.